These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 15638858

  • 1. The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation.
    Cesaro S, Murrone A, Mengoli C, Pillon M, Biasolo MA, Calore E, Tridello G, Varotto S, Alaggio R, Zanesco L, Palù G, Messina C.
    Br J Haematol; 2005 Jan; 128(2):224-33. PubMed ID: 15638858
    [Abstract] [Full Text] [Related]

  • 2. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease.
    Meerbach A, Wutzler P, Häfer R, Zintl F, Gruhn B.
    J Med Virol; 2008 Mar; 80(3):441-54. PubMed ID: 18205222
    [Abstract] [Full Text] [Related]

  • 3. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P.
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [Abstract] [Full Text] [Related]

  • 4. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy.
    Clave E, Agbalika F, Bajzik V, Peffault de Latour R, Trillard M, Rabian C, Scieux C, Devergie A, Socié G, Ribaud P, Adès L, Ferry C, Gluckman E, Charron D, Esperou H, Toubert A, Moins-Teisserenc H.
    Transplantation; 2004 Jan 15; 77(1):76-84. PubMed ID: 14724439
    [Abstract] [Full Text] [Related]

  • 5. A prospective study on modulation of immunosuppression for Epstein-Barr virus reactivation in pediatric patients who underwent unrelated hematopoietic stem-cell transplantation.
    Cesaro S, Pegoraro A, Tridello G, Calore E, Pillon M, Varotto S, Abate D, Barzon L, Mengoli C, Carli M, Messina C.
    Transplantation; 2010 Jun 27; 89(12):1533-40. PubMed ID: 20463647
    [Abstract] [Full Text] [Related]

  • 6. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
    Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K.
    Scand J Infect Dis; 2007 Jun 27; 39(3):235-44. PubMed ID: 17366054
    [Abstract] [Full Text] [Related]

  • 7. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H, Hägglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M, Ringdén O, Sparrelid E, Sundin M, Winiarski J, Yun Z, Ljungman P.
    Transpl Infect Dis; 2009 Oct 27; 11(5):393-9. PubMed ID: 19497070
    [Abstract] [Full Text] [Related]

  • 8. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention?
    Greenfield HM, Gharib MI, Turner AJ, Guiver M, Carr T, Will AM, Wynn RF.
    Pediatr Blood Cancer; 2006 Aug 27; 47(2):200-5. PubMed ID: 16206207
    [Abstract] [Full Text] [Related]

  • 9. Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation.
    Ruf S, Behnke-Hall K, Gruhn B, Bauer J, Horn M, Beck J, Reiter A, Wagner HJ.
    J Clin Virol; 2012 Mar 27; 53(3):186-94. PubMed ID: 22182950
    [Abstract] [Full Text] [Related]

  • 10. [Monitoring of early Epstein-Barr virus reactivation and preemptive therapy after allogeneic hematopoietic stem cell transplantation].
    Lu Y, Wu T, Cao XY, Wang JB, Sun Y, Zhao YL, DA WM, Ji SQ, Tong CR, Lu DP.
    Zhonghua Nei Ke Za Zhi; 2011 May 27; 50(5):383-7. PubMed ID: 21624219
    [Abstract] [Full Text] [Related]

  • 11. Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation.
    Gruhn B, Meerbach A, Häfer R, Zell R, Wutzler P, Zintl F.
    Bone Marrow Transplant; 2003 Jun 27; 31(11):1023-5. PubMed ID: 12774054
    [Abstract] [Full Text] [Related]

  • 12. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation.
    Ahmad I, Cau NV, Kwan J, Maaroufi Y, Meuleman N, Aoun M, Lewalle P, Martiat P, Crokaert F, Bron D.
    Transplantation; 2009 Apr 27; 87(8):1240-5. PubMed ID: 19384173
    [Abstract] [Full Text] [Related]

  • 13. Monitoring of Epstein-Barr viral load in pediatric heart and lung transplant recipients by real-time polymerase chain reaction.
    Benden C, Aurora P, Burch M, Cubitt D, Lloyd C, Whitmore P, Neligan SL, Elliott MJ.
    J Heart Lung Transplant; 2005 Dec 27; 24(12):2103-8. PubMed ID: 16364857
    [Abstract] [Full Text] [Related]

  • 14. The presence of IFNG 3/3 genotype in the recipient associates with increased risk for Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation.
    Bogunia-Kubik K, Mlynarczewska A, Jaskula E, Lange A.
    Br J Haematol; 2006 Feb 27; 132(3):326-32. PubMed ID: 16409297
    [Abstract] [Full Text] [Related]

  • 15. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
    Zallio F, Primon V, Tamiazzo S, Pini M, Baraldi A, Corsetti MT, Gotta F, Bertassello C, Salvi F, Rocchetti A, Levis A.
    Clin Transplant; 2013 Feb 27; 27(4):E491-7. PubMed ID: 23781897
    [Abstract] [Full Text] [Related]

  • 16. [EBV quantification in children after allogeneic hematopoietic stem cell transplantation].
    Hubácek P, Cinek O, Kulich M, Zajac M, Keslová P, Formánková R, Starý J, Sedlácek P.
    Cas Lek Cesk; 2006 Feb 27; 145(4):301-6. PubMed ID: 16639931
    [Abstract] [Full Text] [Related]

  • 17. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
    Lee TC, Savoldo B, Barshes NR, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Scott JD, Goss JA.
    Clin Transplant; 2006 Feb 27; 20(3):389-93. PubMed ID: 16824159
    [Abstract] [Full Text] [Related]

  • 18. Viral-load and B-lymphocyte monitoring of EBV reactivation after allogeneic hemopoietic SCT in children.
    Faraci M, Caviglia I, Morreale G, Lanino E, Cuzzubbo D, Giardino S, Di Marco E, Cirillo C, Scuderi F, Dallorso S, Terranova P, Moroni C, Castagnola E.
    Bone Marrow Transplant; 2010 Jun 27; 45(6):1052-5. PubMed ID: 19855442
    [Abstract] [Full Text] [Related]

  • 19. Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation.
    Peric Z, Cahu X, Chevallier P, Brissot E, Malard F, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Harousseau JL, Moreau P, Milpied N, Coste-Burel M, Imbert-Marcille BM, Mohty M.
    Leukemia; 2011 Jun 27; 25(6):932-8. PubMed ID: 21350556
    [Abstract] [Full Text] [Related]

  • 20. Active Epstein-Barr virus infection after allogeneic stem cell transplantation: re-infection or reactivation?
    Meijer E, Spijkers S, Moschatsis S, Boland GJ, Thijsen SF, van Loon AM, Verdonck LF.
    Transpl Infect Dis; 2005 Mar 27; 7(1):4-10. PubMed ID: 15984942
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.